| Literature DB >> 31572510 |
Lifang Zheng1, Xiaoguang Liu1, Peijie Chen1, Weihua Xiao1.
Abstract
Studies performed previously have indicated that long non-coding RNAs (lncRNAs) may be involved in skeletal muscle regeneration; however, the roles of lncRNAs during the repair of skeletal muscle contusion remain unclear. The present study established a mouse skeletal muscle contusion injury model to identify the roles of lncRNAs that are specifically enriched in the skeletal muscle, namely metastasis-associated lung adenocarcinoma transcript 1 (Malat1), H19, myogenesis-associated lnc (lnc-mg), long intergenic non-protein coding RNAs (linc)-muscle differentiation 1 (linc-MD1), linc-yin yang 1 (linc-YY1) and sirtuin 1-antisense (Sirt1-AS). Morphological analyses revealed that fibrotic scars and regenerating myofibers were formed in the muscle following contusion injury. Gene expression was analyzed by reverse transcription-quantitative polymerase chain reaction. The data revealed that the expression of inflammatory cytokines, myogenic regulatory factors and angiogenic factors increased significantly following skeletal muscle contusion. Additionally, various lncRNAs, including Malat1, H19, lnc-mg, linc-MD1, linc-YY1 and Sirt1-AS were also upregulated. Correlation was also observed between lncRNAs and regulatory factors for skeletal muscle regeneration including transforming growth factor-β1, myogenic differentiation, myogenin, myogenic factor 5 (myf5), myf6, hypoxia-inducible factor-1α and angiopoietin 1. In conclusion, lncRNAs may serve important roles in the regeneration of skeletal muscle following contusion injury, which provides a promising therapy avenue for muscle injury. Copyright: © Zheng et al.Entities:
Keywords: angiogenic factors; inflammatory cytokines; long non-coding RNAs; macrophage; myogenic regulatory factors; skeletal muscle regeneration
Year: 2019 PMID: 31572510 PMCID: PMC6755471 DOI: 10.3892/etm.2019.7871
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Primers used for reverse transcription-quantitative PCR.
| Target gene | Forward primer sequence | Reverse primer sequence |
|---|---|---|
| CD68 | 5′-CAAAGCTTCTGCTGTGGAAAT-3′ | 5′-GACTGGTCACGGTTGCAAG-3′ |
| CD163 | 5′-GCAAAAACTGGCAGTGGG-3′ | 5′-GTCAAAATCACAGACGGAGC-3′ |
| CD206 | 5′-GGATTGTGGAGCAGATGGAAG-3′ | 5′-CTTGAATGGAAATGCACAGAC-3′ |
| IFN-γ | 5′-GCTTTGCAGCTCTTCCTCAT-3′ | 5′-GTCACCATCCTTTTGCCAGT-3′ |
| TNF-α | 5′-CTTCTGTCTACTGAACTTCGGG-3′ | 5′-CACTTGGTGGTTTGCTACGAC-3′ |
| IL-1β | 5′-TGACGTTCCCATTAGACAACTG-3′ | 5′-CCGTCTTTCATTACACAGGACA-3′ |
| IL-6 | 5′-GAACAACGATGATGCACTTGC-3′ | 5′CTTCATGTACTCCAGGTAGCTATGGT-3′ |
| TGF-β1 | 5′-TGCGCTTGCAGAGATTAAAA-3′ | 5′-CGTCAAAAGACAGCCACTCA-3′ |
| IL-10 | 5′-CAAGGAGCATTTGAATTCCC-3′ | 5′-GGCCTTGTAGACACCTTGGTC-3′ |
| Myo D | 5′-GAGCGCATCTCCACAGACAG-3′ | 5′-AAATCGCATTGGGGTTTGAG-3′ |
| Myogenin | 5′-CCAGTACATTGAGCGCCTAC-3′ | 5′-ACCGAACTCCAGTGCATTGC-3′ |
| Myf5 | 5′-GGAATGCCATCCGCTACATT-3′ | 5′-CGTCAGAGCAGTTGGAGGTG-3′ |
| Myf6 | 5′-CCTCAGCCTCCAGCAGTCTT-3′ | 5′-TTCTCCACCACCTCCTCCAC-3′ |
| VEGF | 5′-TAACAGTGAAGCGGAGTG-3′ | 5′-TTTGACCCTTTCCCTTTCCTCG-3′ |
| HIF-1α | 5′-GGCGAGAACGAGAAGAAAAAGATGA-3′ | 5′-GCTCACATTGTGGGGAAGTGG-3′ |
| Angpt1 | 5′-AACCGGATTCAACATGGGCA-3′ | 5′-GAGCGTTGGTGTTGTACTGC-3′ |
| Malat1 | 5′-CACTTGTGGGGAGACCTTGT-3′ | 5′-TGTGGCAAGAATCAAGCAAG-3′ |
| H19 | 5′-TGACTTCATCATCTCCCTCCTGTC-3′ | 5′-GGGTAAATGGGGAAACAGAGTCAC-3′ |
| lnc-mg | 5′-CTGCATCACGGAAGGAGATA-3′ | 5′-AACAATCCATCCTCATTGGC-3′ |
| Sirt1 AS | 5′-AATCCAGTCATTAAACGGTCTACAA-3′ | 5′-TAGGACCATTACTGCCAGAGG-3′ |
| linc-MD1 | 5′-GCAAGAAAACCACAGAGGAGG-3′ | 5′-GTGAAGTCCTTGGAGTTTGAGCA-3′ |
| Linc-YY1 | 5′-AGTTACAGGGAAGTTTGGGCTAC-3′ | 5′-AGGCAAAGGACGGCTGTGAG-3′ |
| GAPDH | 5′-ACTCCACTCACGGCAAATTC-3′ | 5′-TCTCCATGGTGGTGAAGACA-3′ |
IL-1β, interleukin-1β; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; IFN-γ, interferon-γ; IL-10, interleukin-10; TGF-β1, transforming growth factor-β1; MyoD, myogenic differentiation 1; myf5, myogenic factor 5; myf6, myogenic factor 6; HIF-1α, hypoxia-inducible factor-1α; VEGF, vascular endothelial growth factor; Angpt1, angiopoietin 1; Malat1, metastasis associated lung adenocarcinoma transcript 1; lnc-mg, myogenesis-associated long non-coding RNA; Sirt1 AS, sirtuin 1-antisense; linc-MD1, long intergenic non-protein coding RNAs-muscle differentiation 1; linc-YY1, long intergenic non-protein coding RNA-yin yang 1.
Figure 1.Representative images from the hematoxylin and eosin staining of gastrocnemius muscle tissues from the (A) uninjured control group, and (B) 3, (C) 6, (D) 12 and (E) 24 days after injury induction. Thin arrows indicate inflammatory cells, bold arrows indicate central nucleation. Scale bars, 50 µm.
Figure 2.Histological evaluation of scar tissue formation in the injured and uninjured GM by Masson's trichrome staining. Scar tissues are indicated in blue and muscle tissue in red. Representative images of the (A) uninjured control group, (B) muscle contusion group (12 days post-injury) and (C) muscle contusion group (24 days post-injury). (D) Quantification of the scar tissue area following GM injury. Data are presented as the mean ± standard deviation. Scale bars, 100 µm. d, days; GM, gastrocnemius muscle.
Figure 3.Expression of macrophage-specific markers in gastrocnemius muscle samples after muscle contusion. (A) mRNA expression of CD68, (B) CD163 (marker of M2 macrophages) and (C) CD206. Data are presented as the mean ± standard deviation (n=8). *P<0.05, **P<0.01 vs. Con. Con, control; d, days; CD, cluster of differentiation.
Figure 4.Expression of inflammatory factors in gastrocnemius muscle samples following muscle contusion. mRNA expression levels of (A) IL-1β, (B) IL-6, (C) TNF-α, (D) IFN-γ, (E) IL-10 and (F) TGF-β1. Data are presented as the mean ± standard deviation (n=8). *P<0.05, **P<0.01 vs. con. Con, control; IL-1β, interleukin-1β; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; IFN-γ, interferon-γ; IL-10, interleukin-10; TGF-β1, transforming growth factor-β1.
Figure 5.Expression of myogenic regulatory factors in gastrocnemius muscle samples following muscle contusion. mRNA expression levels of (A) MyoD, (B) myogenin, (C) myf5 and (D) myf6. Data are presented as the mean ± standard deviation (n=8). *P<0.05, **P<0.01 vs. Con. Con, control; MyoD, myogenic differentiation 1; myf5, myogenic factor 5; myf6, myogenic factor 6.
Figure 6.Expression of angiogenic factors in gastrocnemius muscle samples following muscle contusion. mRNA expression levels of (A) VEGF, (B) HIF-1α and (C) Angpt1. Data are presented as the mean ± standard deviation (n=8). **P<0.01 vs. Con. Con, control; HIF-1α, hypoxia-inducible factor-1α; VEGF, vascular endothelial growth factor; Angpt1, angiopoietin 1.
Figure 7.Expression of long non-coding RNAs in gastrocnemius muscle samples following muscle contusion. mRNA expression levels of (A) Malat1, (B) H19, (C) lnc-mg, (D) Sirt1 AS, (E) linc-MD1 and (F) linc-YY1. Data are presented as the mean ± standard deviation (n=8). **P<0.01 vs. Con. Con, control; Malat1, metastasis associated lung adenocarcinoma transcript 1; lncRNA, long non-coding RNA; lnc-mg, myogenesis-associated long non-coding RNA; Sirt1 AS, sirtuin 1-antisense; linc-MD1, long intergenic non-protein coding RNAs-muscle differentiation 1; linc-YY1, long intergenic non-protein coding RNA-yin yang 1.
Correlation between the lncRNAs and the specific markers of macrophages, inflammatory cytokines, myogenic regulatory factors and angiogenic factors.
| lncRNA | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Malat1 | H19 | lnc-mg | Sirt1 AS | linc-MD1 | linc-YY1 | |||||||
| Gene | r | P-value | r | P-value | r | P-value | r | P-value | r | P-value | r | P-value |
| CD68 | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. |
| CD163 | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | 0.793 | 0.015 | N.S. | N.S. |
| CD206 | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | 0.862 | 0.002 | N.S. | N.S. |
| TGF-β1 | 0.916 | 0.029 | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | 0.912 | <0.001 | N.S. | N.S. |
| IL-10 | 0.986 | <0.001 | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | 0.896 | <0.001 | N.S. | N.S. |
| IL-6 | 0.598 | 0.005 | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | 0.850 | 0.024 | N.S. | N.S. |
| IL-1β | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. |
| TNF-α | 0.886 | 0.046 | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | 0.906 | 0.034 | N.S. | N.S. |
| IFN-γ | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | 0.884 | 0.037 | N.S. | N.S. |
| MyoD | 0.558 | 0.003 | N.S. | N.S. | N.S. | N.S. | 0.563 | <0.001 | 0.825 | <0.001 | 0.474 | 0.003 |
| myogenin | 0.600 | 0.012 | 0.470 | 0.003 | N.S. | N.S. | 0.535 | <0.001 | 0.773 | <0.001 | 0.423 | 0.007 |
| Myf5 | N.S. | N.S. | 0.797 | 0.001 | N.S. | N.S. | 0.703 | <0.001 | 0.782 | <0.001 | N.S. | N.S. |
| Myf6 | N.S. | N.S. | 0.674 | 0.007 | N.S. | N.S. | 0.620 | 0.001 | 0.897 | 0.039 | N.S. | N.S. |
| VEGF | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. |
| HIF-1α | 0.785 | 0.016 | 0.504 | 0.001 | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. |
| Angpt1 | 0.653 | 0.040 | 0.593 | <0.001 | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. | N.S. |
N.S., not significant; IL-1β, interleukin-1β; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; IFN-γ, interferon-γ; IL-10, interleukin-10; TGF-β1, transforming growth factor-β1; MyoD, myogenic differentiation 1; myf5, myogenic factor 5; myf6, myogenic factor 6; HIF-1α, hypoxia-inducible factor-1α; VEGF, vascular endothelial growth factor; Angpt1, angiopoietin 1; Malat1, metastasis associated lung adenocarcinoma transcript 1; lnc-mg, myogenesis-associated long non-coding RNA; Sirt1 AS, sirtuin 1-antisense; linc-MD1, long intergenic non-protein coding RNAs-muscle differentiation 1; linc-YY1, long intergenic non-protein coding RNA-yin yang 1.